FAS and breast carcinoma: Growing evidences have indicated FAS-AS1 was remarkably down-regulated in breast cancer, non-small lung cancer (NSCLC), gastric cancer, bladder cancer, B-cell lymphoma, and might have a potential as diagnostic biomarker15–19.